Coherus Oncology (CHRS) Debt Ratio (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Debt Ratio data on file, last reported at 0.14 in Q1 2026.

• For the quarter ending Q1 2026, Debt Ratio rose 40.87% year-over-year to 0.14; the trailing twelve-month figure through Mar 2026 stood at 0.14 (up 40.87% YoY), and the FY2025 full-year result was 0.14, up 75.29% from the prior year.
• Debt Ratio slipped to 0.14 in Q1 2026, from 0.14 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.61 in Q1 2023 to a low of 0.05 in Q2 2024.
• A 5-year average of 0.26 and a median of 0.14 in 2025 frame the typical range for Debt Ratio.
• Across the five-year window, Debt Ratio jumped 359.28% in 2022 and plunged 89.66% in 2024, its largest moves.
• Tracing CHRS's Debt Ratio over 5 years: stood at 0.51 in 2022, then dropped by 22.29% to 0.4 in 2023, then slumped by 79.38% to 0.08 in 2024, then jumped by 75.29% to 0.14 in 2025, then declined by 2.63% to 0.14 in 2026.
• Business Quant data shows CHRS's Debt Ratio at 0.14 in Q1 2026, 0.14 in Q4 2025, and 0.07 in Q3 2025.